Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Initial assessment showed that the FITC conjugate peptides recapitulated the pharmacological properties of their unmodified counterparts, with similar binding affinity but reduced cAMP signalling potency for lixisenatide-FITC compared to exendin-4-FITC (Figure 3E, 3F)
Complete Peptide Half-Life Chart The table below summarizes plasma half-life, lyophilized storage temperature, reconstituted stability at 28 C, and typical research dose ranges reported in the peer-reviewed literature and in pharmacokinetic modeling studies
More serious risks include: Low blood sugar (hypoglycemia): Especially when used with other medicines to treat diabetes, low blood sugar may occur, with symptoms such as dizziness, sweating, blurred vision, or confusion
Hepatology 31 , 391398, doi: 10.1002/hep.510310219 (2000)
US$ 29.52
US$ 20.20
US$ 20.61
US$ 23.57
US$ 24.50
US$ 28.68
US$ 27.79
